Literature DB >> 22396075

Expected loss functions as additional measures to assess performance of multiple testing procedures for combination drug dose finding.

Julia N Soulakova1, Allan R Sampson.   

Abstract

There are several measures that are commonly used to assess performance of a multiple testing procedure (MTP). These measures include power, overall error rate (family-wise error rate), and lack of power. In settings where the MTP is used to estimate a parameter, for example, the minimum effective dose, bias is of interest. In some studies, the parameter has a set-like structure, and thus, bias is not well defined. Nevertheless, the accuracy of estimation is one of the essential features of an MTP in such a context. In this paper, we propose several measures based on the expected values of loss functions that resemble bias. These measures are constructed to be useful in combination drug dose response studies when the target is to identify all minimum efficacious drug combinations. One of the proposed measures allows for assigning different penalties for incorrectly overestimating and underestimating a true minimum efficacious combination. Several simple examples are considered to illustrate the proposed loss functions. Then, the expected values of these loss functions are used in a simulation study to identify the best procedure among several methods used to select the minimum efficacious combinations, where the measures take into account the investigator's preferences about possibly overestimating and/or underestimating a true minimum efficacious combination. The ideas presented in this paper can be generalized to construct measures that resemble bias in other settings. These measures can serve as an essential tool to assess performance of several methods for identifying set-like parameters in terms of accuracy of estimation.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Keywords:  average test; dose response; maximum test; minimum effective dose; stepwise procedure

Mesh:

Year:  2012        PMID: 22396075      PMCID: PMC4167965          DOI: 10.1002/pst.542

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  12 in total

1.  Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials.

Authors:  P H Westfall; S Y Ho; B A Prillaman
Journal:  J Biopharm Stat       Date:  2001       Impact factor: 1.051

2.  Resampling-based and other multiple testing strategies with application to combination drug trials with factorial designs.

Authors:  Julia N Soulakova
Journal:  Stat Methods Med Res       Date:  2010-07-28       Impact factor: 3.021

3.  Closure procedures for monotone bi-factorial dose-response designs.

Authors:  M Hellmich; W Lehmacher
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

4.  On identifying effective and superior drug combinations via Holm's procedure based on the min tests.

Authors:  Julia N Soulakova
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

5.  Comparison of several testing strategies for combination drug efficacy trials based on the closure principle.

Authors:  Julia N Soulakova
Journal:  Stat Med       Date:  2009-01-30       Impact factor: 2.373

6.  Resampling in multiple-dose factorial designs.

Authors:  Peter Frommolt; Martin Hellmich
Journal:  Biom J       Date:  2009-12       Impact factor: 2.207

7.  Multiple test procedures for dose finding.

Authors:  A C Tamhane; Y Hochberg; C W Dunnett
Journal:  Biometrics       Date:  1996-03       Impact factor: 2.571

8.  Simultaneous confidence bands for comparisons to placebo, with application to detecting the minimum effective dose.

Authors:  Julia N Soulakova; Allan R Sampson; Gang Jia; Leon J Gleser
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

9.  Testing for the existence of a desirable dose combination.

Authors:  H M Hung; G Y Chi; R J Lipicky
Journal:  Biometrics       Date:  1993-03       Impact factor: 2.571

10.  On Identifying Minimum Efficacious Doses in Combination Drug Trials.

Authors:  Julia N Soulakova; Allan R Sampson
Journal:  Stat Biopharm Res       Date:  2009       Impact factor: 1.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.